NCT06829316Not yet recruiting
Epigenetic and Neurochemical Correlates of Bipolar Disorder
Epigenetic and Neurochemical Correlates of Bipolar Disorder: Investigating Key Biomarkers
Source: ClinicalTrials.gov · Last updated 17 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Aim of Study: * To assess DNA methylation of the IL1-B gene in individuals with BD compared to healthy controls. * To evaluate the expression of 5-hydroxytryptamine (serotonin) receptors in BD and shed more light into its role into the pathophysioogy of BD. * To measure differences of glutamic acid levels between study groups. * To investigate correlations between these biomarkers among study groups, and their alignment with clinical presentations.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 108 (estimated)
- First submitted
- 11 Feb 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 30 Mar 2026
- Lead sponsor
- Assiut University
- Diseases
- Bipolar disorder
- NCT number
- NCT06829316
What you commit to
- Study type: Observational
- Planned participants: 108
- From 1 Mar 2025 to the primary completion date, 30 Mar 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Patients who have a concurrent severe illness or inflammatory disorders will be excluded. (e.g., other CNS disorders, autoimmune diseases, cancers... etc.)
Other
- Current substance abuse.
Who the study is looking for
- \- Adults aged 18-45 with diagnosis of BD type I.
- Informed consent.
Age in the registry: 18 months to 45 months · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.